Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Neoplasm Metastasis 4Pancreatic Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumors 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Endometrial Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-menopausal Breast Cancer 1Non-Small Cell Lunch Cancer 1Non Castrate Metastatic Prostate Cancer 1Neoplasms 1Nasopharyngeal Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Locally Advanced Solid Tumor 1

Interventions

Cyclophosphamide 27Rituximab 26fludarabine phosphate 18Filgrastim 17fludarabine 13Lenalidomide 13Peripheral Blood Stem Cell Transplantation 12Bortezomib 12Bendamustine Hydrochloride 12ibrutinib 9venetoclax 8Etoposide 8Paclitaxel 7Flow Cytometry 7Cyclosporine 7tanespimycin 6aldesleukin 6Prednisone 6Magnetic Resonance Spectroscopy 6Cytarabine 6Biopsy 6obinutuzumab 5Vorinostat 5Tacrolimus 5Radiotherapy 5Polymerase Chain Reaction 5Melphalan 5Gemcitabine 5sargramostim 4belinostat 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell, Marginal Zone × NVP-BKM120 × Clear all
NCT02049541 2022-06-30

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
18 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡